Finance

Lists
LAURUSLABS:NSE
Laurus Labs Ltd
₹2,323.00
-1.06%
(-25.00) 1D
Nov 3, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for LAURUSLABS...
Open
₹2,350.10
High
₹2,354.90
Low
₹2,252.40
Mkt. cap
1.25T
Avg. vol.
1.93M
Volume
4.03M
Dividend
0.09%
Quarterly dividend
₹0.55
Ex-dividend date
May 8, 2026
P/E ratio
93.76
52-wk high
₹2,405.50
52-wk low
₹917.95
EPS
₹24.78
Shares outstanding
106.44M
No. of employees
7K
Open
₹2,350.10
High
₹2,354.90
Low
₹2,252.40
Mkt. cap
1.25T
Avg. vol.
1.93M
Volume
4.03M
Dividend
0.09%
Quarterly dividend
₹0.55
Ex-dividend date
May 8, 2026
P/E ratio
93.76
52-wk high
₹2,405.50
52-wk low
₹917.95
EPS
₹24.78
Shares outstanding
106.44M
No. of employees
7K
News stories
From web sources and news partners
Profile
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States. Wikipedia
About Laurus Labs Ltd
CEOSatyanarayana Chava
Employees7.06K
Founded2005
Headquarters-
SectorPharmaceutical industry
Last report
Oct 29, 2026
Fiscal period
Q2 2027
₹8.16 / ₹7.18
+13.69%beat
Revenue / Est. (INR)
22.06B / 21.01B
+4.99%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
17.78B
18.12B
20.26B
22.06B
Cost of goods sold
6.95B
8.34B
7.56B
8.16B
Cost of revenue
6.95B
8.34B
7.56B
8.16B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.29B
2.57B
2.59B
2.66B
Operating expense
7.24B
5.86B
7.56B
7.67B
Total operating expenses
14.19B
14.20B
15.12B
15.83B
Operating income
3.60B
3.92B
5.14B
6.23B
Other non operating income
57.60M
-330.90M
91.80M
130.10M
EBT including unusual items
3.25B
3.62B
4.81B
5.91B
EBT excluding unusual items
3.25B
3.62B
4.81B
5.91B
Income tax expense
734.50M
794.60M
1.19B
1.55B
Effective tax rate
22.58%
21.98%
24.79%
26.23%
Other operating expenses
3.74B
2.07B
3.73B
3.74B
Net income
2.52B
2.79B
3.68B
4.41B
Net profit margin
14.15%
15.41%
18.14%
20.01%
Earnings per share
4.65
5.17
6.80
8.16
Interest and investment income
-
65.70M
-
-
Interest expense
-387.90M
-307.60M
-422.20M
-441.00M
Net interest expenses
-387.90M
-241.90M
-422.20M
-441.00M
Depreciation and amortization charges
1.21B
1.22B
1.24B
1.27B
EBITDA
4.62B
5.12B
6.34B
7.49B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps